Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: Its enhancement by interferon-gamma (IFN-γ) and IL-12 and fluctuations in association with disease activity

Clinical and Experimental Immunology

Volumn 112, Issue 3, 1998, Pages 403-409

  Seo, N ^a   Tokura, Y ^a   Matsumoto, K ^a   Furukawa, F ^a   Takigawa, M ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cutaneous T cell lymphoma; Cytotoxic T lymphocyte; Interferongamma IL 12; Sezary syndrome

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA; GAMMA INTERFERON; INTERLEUKIN 12; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE ACTIVITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY SYNDROME; T CELL LYMPHOMA;

ANTIGENS, NEOPLASM; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SEZARY SYNDROME; SKIN NEOPLASMS; TH2 CELLS; TUMOR CELLS, CULTURED;

EID: 0031832145     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00599.x     Document Type: Article

References (44)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
2. Boon T, Cerottini JC, Van Der Eynde B, Van Der Brugenn P, Van Pel A. Tumor antigen recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-65.
3. Rotzschke O, Falk K. Naturally occurring peptide antigens derived from the MHC class I restricted processing pathway. Immunol Today 1991; 12:447-55.
4. Parham P. Pictures of MHC restriction. Nature 1996; 384:109-10.
5. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A, Long EO. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995; 267:1016-8.
6. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-58.
7. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996; 183:7-11.
8. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
9. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988; 319:1676-80.
10. Siegel JP. Effects on interferon-γ on the activation of human T lymphocytes. Cell Immunol 1988; 111:461-72.
11. Seo N, Egawa K. Utilization of leucine methyl ester for generation of hybridomas producing monoclonal antibodies specific to tumor-associated antigens. Cancer Immunol Immunother 1994; 38:277-80.
12. Edelson R. Cutaneous T cell lymphoma (mycosis fungoides, Sézary syndrome and other variants). J Am Acad Dermatol 1980; 2:89-106.
13. Heald P, Edelson R. The immunobiology of cutaneous T-cell lymphoma. J Natl Cancer Inst 1991; 83:400-4.
14. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90-94.
15. Saed G, Fivenson DP, Naidu Y, Nickoloff J. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sézary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103:29-33.
16. Tendler CL, Burton JD, Danielpour D, Charley M, Mccoy JP, Pittelkow MR, Waldmann TA. Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 1994; 54:4430-5.
17. Yagi H, Tokura Y, Furukawa F, Takigawa M. CD7-positive Sézary syndrome with a Th1 cytokine profile. J Am Acad Dermatol 1996; 34:368-74.
18. Heald PW, Edelson RL., Lymphoma, pseudolymphoma and related conditions. In: Fitzpatrick TB, ed. Dermatology in general medicine, 4th edn. New York: McGraw-Hill, 1993: 1285-312.
19. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T cell lymphoma: abnormal cytokine production by Sézary T cells. Arch Dermatol 1993; 129:486-9.
20. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I-associated tumor specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996; 107:392-7.
21. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-γ. J Invest Dermatol 1996; 107:827-32.
22. Vowels BR, Lessin SR, Cassin M, Benoit BM, Rook AH. Normalization of cytokine secretion patterns and immune function following disappearance of malignant clone from the peripheral blood of a Sézary syndrome patient. J Invest Dermatol 1993; 100:556-62.
23. Lutzner MA, Jordan HW. The ultrastructure of an abnormal cell in Sézary's syndrome. Blood 1968; 31:719-26.
24. Edelson RL. Pathogenesis of T-cell lymphoma of skin. J Am Acad Dermatol 1983; 9:957-60.
25. Willemze R, Van Vloten WA, Hermans J. Damsteeg MJ, Meijer CJ. Diagnostic criteria in Sézary syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81:392-7.
26. Ikuta K, Ogura T, Shimizu A, Honjo T. Low frequency of somatic mutation in β-chain variable region genes of human T-cell receptors. Proc Natl Acad Sci USA 1985; 82:7701-5.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
28. Seo N, Egawa K. Suppression of cytotoxic T lymphocyte activity by γ/δ T cells in tumor bearing mice. Cancer Immunol Immunother 1995; 40:358-66.
29. Vonderheid EC, Bigler RD, Greenberg AS, Neukum SJ, Micaily B. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sézary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994; 17:255-63.
30. Labaatide WB, Rana MT, Barker CR. A new monoclonal antibody (CH-F42) recognizes a CD7 subset of normal T-lymphocytes and circulating malignant cells in adult T-cell lymphoma-leukemia and Sézary syndrome. Blood 1990; 76:1361-8.
31. + T cells: comparative analysis of skin and blood in mycosis fungoides/ Sézary syndrome relative to normal blood values. J Am Acad Dermatol 1990; 22:602-7.
32. Marti RM, Eatrach T, Reverter JC, Mascaro JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127:1511-6.
33. Manetti R, Parronchi P, Giudizi MG, Piccinni M-P, Maggi E, Trinchieri G, Romagnani S. Natural killer cell stimulatory factor (IL-12) induces Th1-type specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199-204.
34. Kobayashi M, Fitz L, Hewick RM et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827-45.
35. Powrie F, Coffman RL. Cytokine regulation of T-cell function; potential for therapeutic intervention. Immunol Today 1993; 14:270-4.
36. Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988; 141:2349-51.
37. Kawakami Y, Custer MC, Rosenberg SA, Lotze MT. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol 1989; 142:3452-61.
38. Salvucci O, Chouaib FM, Moreau JL, Theze J, Chehimi J, Chouaib S. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4. Eur J Immunol 1996; 26:2736-41.
39. Peleman R, Wu J, Rargeas C, Delespsse G. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 1989; 170:1751-6.
40. Gajewski TF, Fitch FW. Anti-proliferative effect of IFNγ in immune regulation. I. IFNγ inhibits the proliferation of TH2 hut not TH1 murine HTL clones. J Immunol 1988; 140:4245-52.
41. Imai K, Ng A-K, Glassy MC, Ferrone S. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol 1981; 127:505-8.
42. Chan SH, Perussia B, Gupta JW et al. Induction of interferon-γ production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J Exp Med 1991; 173:869-79.
43. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9.
44. Rook AH, Kubin M, Cassin M et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995; 154:1491-8.